FDA Accepts Supplemental Application for Jentadueto XR by Boehringer Ingelheim
The FDA has accepted a supplemental application for Jentadueto XR (NDA208026) from Boehringer Ingelheim.
Therapeutic Area
Therapeutic area intelligence for Biguanide with 3 indexed intelligence signals across regulatory, clinical, competitive, and market developments.
The FDA has approved a supplemental application for SYNJARDY (NDA206111), containing empagliflozin and metformin hydrochloride, submitted by Boehringer Ingelheim.
No catalysts indexed for this entity yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.